Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Reaching consensus in relapsed/refractory ALL in AYAs.

Blood advances·2026

Same author

Inflammatory immune modulators of AML lung infiltration and respiratory failure.

Nature immunology·2026

Same author

Detection of MEN1 resistance mutations in cell-free DNA from acute leukemia patients treated with menin inhibitors.

Blood cancer journal·2026

Same author

Cell autonomous inflammation in VEXAS is mediated by cGAS-STING.

bioRxiv : the preprint server for biology·2026

Same author

RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcoma.

Blood cancer discovery·2026

Same author

Toxicity from asparaginase during acute lymphoblastic leukemia induction: A report from the Children's Oncology Group.

Blood advances·2026

Search research articles

Related Experiment Video

Updated: Mar 9, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Beating the Clock in T-cell Acute Lymphoblastic Leukemia.

William L Carroll¹, Iannis Aifantis², Elizabeth Raetz³

¹Department of Pediatrics, Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York. william.carroll@nyumc.org.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

|December 24, 2016

Summary

CDK4/6 inhibitors show promise for T-cell acute lymphoblastic leukemia (T-ALL) when combined with dexamethasone and everolimus. However, they are antagonistic with chemotherapy in preclinical T-ALL models.

More Related Videos

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL

Published on: July 19, 2024

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

Related Experiment Videos

Last Updated: Mar 9, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL

Published on: July 19, 2024

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

Area of Science:

Oncology
Molecular Biology
Pharmacology

Background:

T-cell acute lymphoblastic leukemia (T-ALL) remains a challenging hematologic malignancy.
Identifying effective therapeutic strategies for T-ALL is crucial.
Targeting cell cycle pathways is a potential approach for T-ALL treatment.

Purpose of the Study:

To investigate the synergistic or antagonistic effects of CDK4/6 inhibition in combination with other agents in T-ALL.
To explore the therapeutic potential of combining cyclin-dependent kinase (CDK) inhibitors with glucocorticoids and mTOR inhibitors in T-ALL.

Main Methods:

Preclinical models of T-cell acute lymphoblastic leukemia (T-ALL) were utilized.
The effects of CDK4/6 inhibition were evaluated in combination with dexamethasone, everolimus, and conventional chemotherapy agents.

Main Results:

CDK4/6 inhibition demonstrated synergistic effects when combined with dexamethasone and everolimus in T-ALL models.
Conversely, CDK4/6 inhibition showed antagonistic effects when combined with conventional chemotherapy in T-ALL models.

Conclusions:

Combination therapy involving CDK4/6 inhibitors, glucocorticoids (dexamethasone), and mTOR inhibitors (everolimus) presents a unique therapeutic opportunity for T-ALL.
These findings suggest a potential new treatment paradigm for T-ALL, warranting further clinical investigation.